Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

Artivion (NYSE: AORT) presented promising clinical data from Endospan's NEXUS TRIOMPHE IDE trial at the 105th AATS Annual Meeting.

Rhea-AI Summary

Artivion (NYSE: AORT) presented promising clinical data from Endospan's NEXUS TRIOMPHE IDE trial at the 105th AATS Annual Meeting. The study evaluated 54 high-risk patients with chronic aortic dissection treated with the NEXUS stent graft system. At 30 days post-treatment, the results showed a significant 63% reduction in Major Adverse Events (MAE) rate at 13.0% compared to the 35.0% performance goal (p0.001). The technical failure rate was notably low at (p<0.001). The NEXUS device represents a minimally invasive alternative to open aortic arch replacement for high-risk patients, potentially extending treatment options to previously untreatable cases.

Positive

• Significant 63% reduction in Major Adverse Events rate (13.0% vs 35.0% performance goal)
• Extremely low technical failure rate of 1.9% vs 30.0% performance goal
• Potential market expansion by offering treatment to high-risk patients previously considered untreatable

Negative

• None.

Argus Session date unavailable

+1.89% session move Open Argus

Details

News Market Reaction – AORT

The recorded move for AORT in the trading session of this news was +1.89%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal

ATLANTA, May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105^th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS.  Patients enrolled were at high risk for open surgical repair.

Dr. Bradley Leshnower, Professor of Surgery and Director of Thoracic Aortic Surgery, Emory University, presented the data from the NEXUS US IDE trial in an abstract titled, Endovascular Aortic Arch Repair Using a Novel Single-Branch Arch Stent Graft for Chronic Dissection: 30-Day Outcomes of the TRIOMPHE FDA Pivotal Study.

The data demonstrate statistically significant improvement in clinical outcomes and device technical performance compared with the performance goals set forth in the FDA-approved investigational device exemption (IDE).

	TRIOMPHE	Performance Goal	p Value
MAEs* >=1	13.0 %	35.0 %	p <0.001
Technical Failure	1.9 %	30.0 %	p <0.001

*Major adverse events (MAEs) = mortality, disabling stroke, permanent paralysis/paraplegia, renal failure, aortic rupture, or development of new dissections in the thoracic aorta or brachiocephalic artery requiring intervention.

Dr. Leshnower said, "The 30-day results from the TRIOMPHE study demonstrate that aneurysms due to chronic aortic arch dissection involving the aortic arch can be successfully treated with this novel off-the-shelf stent graft system.  The NEXUS device provides an excellent, minimally invasive alternative to open aortic arch replacement in select patients at high risk for open surgery. This novel technology will extend treatment to patients who previously would not be offered therapy due to prohibitive risk"

"We are pleased with the 30-day results and look forward to seeing the one-year outcomes," said Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. "These results further validate this important therapeutic option for patients with aortic arch disease."

About the NEXUS TRIOMPHE Clinical Trial
The NEXUS TRIOMPHE trial is the US IDE study evaluating the NEXUS device in the endovascular treatment of chronic aortic dissection, either primary type B or residual dissection after prior type A repair, or aneurysm (not reported here). Inclusion criteria include the patient being high risk for open surgical repair. The clinical module of the PMA is anticipated to be filed after completion of one year of follow up with the 54 patients in the chronic aortic dissection statistical primary cohort.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

References

1. Leshnower B: Endovascular Aortic Arch Repair Using a Novel Single-Branch Arch Stent Graft for Chronic Dissection: 30-Day Outcomes of the TRIOMPHE FDA Pivotal Study.  Presented May 3, 2025 at American Association of Thoracic Surgeons 105^th annual meeting.

Contacts:

Artivion          Lance A. Berry                                               Executive Vice President & Chief Financial Officer Phone: 770-419-3355	Gilmartin Group LLC Brian Johnston / Laine Morgan Phone: 332-895-3222 investors@artivion.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-presentation-of-new-clinical-data-from-nexus-triomphe-ide-trial-at-the-105th-american-association-for-thoracic-surgery-aats-annual-meeting-302445689.html

SOURCE Artivion, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key findings from Artivion's (AORT) NEXUS TRIOMPHE trial presented at AATS 2025?

The trial showed a 63% reduction in Major Adverse Events (13.0% vs 35.0% performance goal) and a 1.9% technical failure rate (vs 30.0% goal) in treating chronic aortic dissection patients at 30 days post-treatment.

How does the NEXUS stent graft system benefit high-risk aortic arch patients?

NEXUS provides a minimally invasive alternative to open aortic arch replacement for high-risk patients, making treatment possible for those previously considered too risky for traditional surgery.

What was the patient population size in the NEXUS TRIOMPHE IDE trial?

The trial analyzed clinical outcomes across a cohort of 54 patients with chronic aortic dissection who were at high risk for open surgical repair.

What are the Major Adverse Events (MAEs) measured in the NEXUS TRIOMPHE trial?

MAEs include mortality, disabling stroke, permanent paralysis/paraplegia, renal failure, aortic rupture, or development of new dissections in the thoracic aorta or brachiocephalic artery requiring intervention.